Corxel Acquires Worldwide (Excluding Greater China) Rights to an Oral Small Molecule GLP-1 Ra for the Treatment of Obesity and Diabetes
Corxel獲取了一種口服小分子GLP-1受體激動劑在全球(不包括大中華地區)用於治療肥胖和糖尿病的權利
Corxel Acquires Worldwide (Excluding Greater China) Rights to an Oral Small Molecule GLP-1 Ra for the Treatment of Obesity and Diabetes
Corxel獲取了一種口服小分子GLP-1受體激動劑在全球(不包括大中華地區)用於治療肥胖和糖尿病的權利
使用瀏覽器的分享功能,分享給你的好友吧